Patents by Inventor Mikio Nishizawa

Mikio Nishizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound, medicine, anti-inflammatory, cosmetic, food and drink, and method for producing compound
    Patent number: 9573920
    Abstract: A compound is represented by Formula (I) or (II) described below. A medicine includes, as an active ingredient, a compound represented by Formula (I), (II), or (III) described below.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 21, 2017
    Assignees: AMINO UP CHEMICAL CO., LTD, THE RITSUMEIKAN TRUST
    Inventors: Yukinobu Ikeya, Mikio Nishizawa, Takehito Miura
  • Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same
    Patent number: 9464292
    Abstract: The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 11, 2016
    Assignees: AMINO UP CHEMICAL CO., LTD, KANSAI MEDICAL UNIVERSITY
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • COMPOUND, MEDICINE, ANTI-INFLAMMATORY, COSMETIC, FOOD AND DRINK, AND METHOD FOR PRODUCING COMPOUND
    Publication number: 20160207901
    Abstract: A compound is represented by Formula (I) or (II) described below. A medicine includes, as an active ingredient, a compound represented by Formula (I), (II), or (III) described below.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 21, 2016
    Inventors: Yukinobu IKEYA, Mikio NISHIZAWA, Takehito MIURA
  • SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF INOS AND COMPOSITION COMPRISING THE SAME
    Publication number: 20150191733
    Abstract: The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.
    Type: Application
    Filed: December 12, 2014
    Publication date: July 9, 2015
    Applicants: AMINO UP CHEMICAL CO., LTD, KANSAI MEDICAL UNIVERSITY
    Inventors: Tadayoshi OKUMURA, Mikio NISHIZAWA, Yasuo KAMIYAMA, Koji WAKAME, Takehito MIURA
  • Method for controlling the amount of gene product, and agent for controlling the amount of gene product
    Patent number: 8975023
    Abstract: The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: March 10, 2015
    Assignees: Amino Up Chemical Co., Ltd, Kansai Medical University
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same
    Patent number: 8927704
    Abstract: The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: January 6, 2015
    Assignees: Amino Up Chemical Co., Ltd, Kansai Medical University
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • METHOD FOR CONTROLLING THE AMOUNT OF GENE PRODUCT, AND AGENT FOR CONTROLLING THE AMOUNT OF GENE PRODUCT
    Publication number: 20130177909
    Abstract: The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.
    Type: Application
    Filed: February 19, 2013
    Publication date: July 11, 2013
    Applicants: KANSAI MEDICAL UNIVERSITY, AMINO UP CHEMICAL CO., LTD.
    Inventors: Tadayoshi OKUMURA, Mikio NISHIZAWA, Yasuo KAMIYAMA, Koji WAKAME, Takehito MIURA
  • Method for controlling the amount of gene product, and agent for controlling the amount of gene product
    Patent number: 8399424
    Abstract: The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: March 19, 2013
    Assignees: Amino Up Chemical Co., Ltd, Kansai Medical University
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • SENSE OLOGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME
    Publication number: 20100248364
    Abstract: The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.
    Type: Application
    Filed: June 7, 2007
    Publication date: September 30, 2010
    Applicant: Amino Up Chemical Co., Ltd.
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • METHOD FOR CONTROLLING THE AMOUNT OF GENE PRODUCT, AND AGENT FOR CONTROLLING THE AMOUNT OF GENE PRODUCT
    Publication number: 20100227318
    Abstract: The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.
    Type: Application
    Filed: June 7, 2007
    Publication date: September 9, 2010
    Applicants: AMINO UP CHEMICAL CO., LTD., KANSAI MEDICAL UNIVERSITY
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • Antibodies specific for phosphorylation sites and screening methods using the same antibodies
    Patent number: 7417124
    Abstract: Polyclonal antibody specific for a phosphorylated linker region in Smad2 and/or Smad3.
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: August 26, 2008
    Assignees: Zeria Pharmaceutical Co., Ltd., Kansai Medical University
    Inventors: Koichi Matsuzaki, Toshihito Seki, Masanori Matsushita, Yoshiya Tahashi, Fukiko Furukawa, Yasushi Sugano, Shigeo Mori, Hideo Yamagata, Katsunori Yoshida, Mikio Nishizawa, Junichi Fujisawa, Keiko Inoue, legal representative, Kyoichi Inoue
  • Antibodies specific for phosphorylation sites and screening methods using the same antibodies
    Publication number: 20050079559
    Abstract: Polyclonal antibody specific for a phosphorylated linker region in Smad2 and/or Smad3.
    Type: Application
    Filed: April 13, 2004
    Publication date: April 14, 2005
    Inventors: Koichi Matsuzaki, Toshihito Seki, Masanori Matsushita, Yoshiya Tahashi, Fukiko Furukawa, Yasushi Sugano, Shigeo Mori, Hideo Yamagata, Katsunori Yoshida, Mikio Nishizawa, Junichi Fujisawa, Kyoichi Inoue, Keiko Inoue